China Renews Reimbursement for Three Hutchmed Drugs

MT Newswires Live12-08

Hutchmed (HKG:0013) said three of its oncology medicines, Elunate, Orpathys, and Sulanda, will remain covered under China's updated National Reimbursement Drug List effective Jan. 1, 2026, according to a Monday Hong Kong bourse filing.

Elunate's coverage has been expanded to include pMMR advanced endometrial cancer in combination with Tyvyt, alongside its existing listing for metastatic colorectal cancer.

Orpathys continues to be reimbursed for MET exon 14 skipping non-small cell lung cancer, while Sulanda remains covered for advanced non-functional neuroendocrine tumors.

The company added that Tazverik has been included in China's first National Commercial Health Insurance Innovative Drug List, which supports reimbursement via commercial medical insurance products, according to the filing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589073678?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 09:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589073678","market":"sg","top_or_hot":-1,"title":"China Renews Reimbursement for Three Hutchmed Drugs","media":"MT Newswires Live","content":"<html><body><p> Hutchmed (HKG:0013) said three of its oncology medicines, Elunate, Orpathys, and Sulanda, will remain covered under China's updated National Reimbursement Drug List effective Jan. 1, 2026, according to a Monday Hong Kong bourse filing.</p><p>Elunate's coverage has been expanded to include pMMR advanced endometrial cancer in combination with Tyvyt, alongside its existing listing for metastatic colorectal cancer.</p><p>Orpathys continues to be reimbursed for MET exon 14 skipping non-small cell lung cancer, while Sulanda remains covered for advanced non-functional neuroendocrine tumors.</p><p>The company added that Tazverik has been included in China's first National Commercial Health Insurance Innovative Drug List, which supports reimbursement via commercial medical insurance products, according to the filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Renews Reimbursement for Three Hutchmed Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Renews Reimbursement for Three Hutchmed Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-08 09:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Hutchmed (HKG:0013) said three of its oncology medicines, Elunate, Orpathys, and Sulanda, will remain covered under China's updated National Reimbursement Drug List effective Jan. 1, 2026, according to a Monday Hong Kong bourse filing.</p><p>Elunate's coverage has been expanded to include pMMR advanced endometrial cancer in combination with Tyvyt, alongside its existing listing for metastatic colorectal cancer.</p><p>Orpathys continues to be reimbursed for MET exon 14 skipping non-small cell lung cancer, while Sulanda remains covered for advanced non-functional neuroendocrine tumors.</p><p>The company added that Tazverik has been included in China's first National Commercial Health Insurance Innovative Drug List, which supports reimbursement via commercial medical insurance products, according to the filing.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2589073678","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589073678","pubTimestamp":1765157215,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hutchmed  said three of its oncology medicines, Elunate, Orpathys, and Sulanda, will remain covered under China's updated National Reimbursement Drug List effective Jan. 1, 2026, according to a Monday Hong Kong bourse filing.Elunate's coverage has been expanded to include pMMR advanced endometrial cancer in combination with Tyvyt, alongside its existing listing for metastatic colorectal cancer.Orpathys continues to be reimbursed for MET exon 14 skipping non-small cell lung cancer, while Sulanda remains covered for advanced non-functional neuroendocrine tumors.The company added that Tazverik has been included in China's first National Commercial Health Insurance Innovative Drug List, which supports reimbursement via commercial medical insurance products, according to the filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1588":"回港中概股","00013":"和黄医药","BK1587":"次新股"},"translate_title":"中国续签和黄医药三种药物的报销","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":0.9},"content_text":"Hutchmed (HKG:0013) said three of its oncology medicines, Elunate, Orpathys, and Sulanda, will remain covered under China's updated National Reimbursement Drug List effective Jan. 1, 2026, according to a Monday Hong Kong bourse filing.Elunate's coverage has been expanded to include pMMR advanced endometrial cancer in combination with Tyvyt, alongside its existing listing for metastatic colorectal cancer.Orpathys continues to be reimbursed for MET exon 14 skipping non-small cell lung cancer, while Sulanda remains covered for advanced non-functional neuroendocrine tumors.The company added that Tazverik has been included in China's first National Commercial Health Insurance Innovative Drug List, which supports reimbursement via commercial medical insurance products, according to the filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589073678","isCrawlerRequest":true}